Company intelligence / Profile preview
Triumvira Immunologics
Austin*, Texas, USAtriumvira.com ↗
- Ownership
- Private
- Employees
- ~50
- Development stage
- Phase 1
01
Overview
Triumvira’s TAC platform has demonstrated promising preclinical and early clinical results, showing selective tumor recognition and controlled T cell activation with reduced toxicity compared to conventional CAR-T or engineered TCR therapies. Interim data from the ongoing Phase 1/2 study of autologous TAC-T cells targeting CLDN18.2+ advanced solid tumors indicate safety and efficacy signals in this hard-to-treat population.[7]
- Therapeutic areas
- Oncology
- Modalities
- Autologous T cell therapiesAllogeneic T cell therapiesCell therapy (TAC-T cells)
- Industry
- Biotech
02
Drug pipeline
9 assets8 more assets in the full pipeline.
Request access →03
Partnerships
Bayer Leaps is a notable investor and partner; other investors include Bloom Burton & Co., Myeloma Investment Fund.[4][9][10] No major pharma co-development deals disclosed.
Beyond the preview
Go deeper on Triumvira Immunologics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Triumvira Immunologics.